Novartis AG (NVS)
| Market Cap | 212.12B |
| Revenue (ttm) | 51.72B |
| Net Income (ttm) | 11.94B |
| Shares Out | 1.98B |
| EPS (ttm) | 5.87 |
| PE Ratio | 17.76 |
| Forward PE | 12.90 |
| Dividend | $3.78 (3.52%) |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 1,885,846 |
| Open | 106.11 |
| Previous Close | 106.91 |
| Day's Range | 106.11 - 107.50 |
| 52-Week Range | 92.35 - 120.92 |
| Beta | 0.51 |
| Analysts | Hold |
| Price Target | 123.67 (+15.25%) |
| Earnings Date | Jan 31, 2025 |
About NVS
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $123.67, which is an increase of 15.25% from the latest price.
News
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis: Strong Execution With A P/E Discount
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic...
Novartis: Just What The Doctor Ordered
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost m...
Novartis agrees to acquire Anthos for up to $3.1 bln
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company...
Novartis is considering further acquisitions to drive growth, CEO says
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose...
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide.
Novartis beats consensus on Q4 earnings
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues.
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc 1 , +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
10 Undervalued Dividend Growth Stocks: January 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an...
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary ...
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet...
Novartis loses emergency bid to block Entresto generic in US
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug En...
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Novartis AG (NYSE:NVS) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vo...
Novartis CEO: We need to get Europe to pay its fair share
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite Bi...
Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination ...
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 p...
AI, vaccine distrust, & the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.